Armata Pharmaceuticals Receives Agreement from FDA on Initial Pediatric Study Plan for AP-SA02 for the Treatment of Complicated Staphylococcus aureus Bacteremia

2026-07-13 07:00:00

Fulfills important regulatory milestone for AP-SA02 on the path toward a future BLA and supports expansion into pediatric patients LOS ANGELES, July 13, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has received agreement from the U.S. Food and Drug Administration (the "FDA") on an Agreed Initial Pediatric Study Plan ("Agreed iPSP"), which establishes the agreed regulatory framework for the future evaluation of AP-SA02 for the adjunct treatment of complicated Staphylococcus aureus bacteremia ("SAB") in pediatric patients. Agreement with the FDA on an iPSP is a regulatory requirement that must be met prior to submitting a Biologics License Application ("BLA").

Armata Pharmaceuticals Receives $2.5 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support AP-SA02

2026-06-23 07:00:00

Supports Phase 3 readiness of AP-SA02 Non-dilutive DoD funding totals $28.7M to date LOS ANGELES, June 23, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has received an additional $2.5 million of non-dilutive funding pursuant to a previously announced Department of Defense (DoD) award, received through the Medical Technology Enterprise Consortium (MTEC) and managed by the Naval Medical Research Command (NMRC) – Naval Advanced Medical Development (NAMD) with funding from the Defense Health Agency and Joint Warfighter Medical Research Program. The award, which now totals $28.7 million, supports the development of Armata's lead clinical candidate AP-SA02, for adjunct treatment of complicated Staphylococcus aureus ("S.

Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update

2026-05-13 16:30:00

Entered into secured credit agreement with Innoviva for $25 million maturing in 2029 LOS ANGELES, May 13, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its first quarter ended March 31, 2026, and provided a corporate update. "Our top priority in 2026 is advancing Armata's lead Staphylococcus aureus ("S.

Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02

2026-05-07 07:00:00

Enables more frequent FDA engagement, rolling Biologic License Application review, and the potential for Accelerated Approval and Priority Review upon successful clinical development Advances AP-SA02 on a faster path to potential approval and patient access LOS ANGELES, May 7, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the U.S. Food and Drug Administration (the "FDA") has granted Fast Track Designation to AP-SA02, the Company's intravenously administered Staphylococcus aureus ("S. aureus") multi-phage product candidate, for adjunct treatment of complicated bacteremia caused by methicillin-sensitive S.

Armata Pharmaceuticals Announces Structural Biology Publication in "Communications Biology"

2026-05-04 07:00:00

Describes structure of phage P7-1, included in Armata's Pseudomonas aeruginosa phage cocktail, AP-PA02 LOS ANGELES, May 4, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced a paper in Communications Biology, a peer-reviewed journal from Nature Portfolio. The publication, titled, "Structural atlas of Pakpunavirus P7-1 reveals determinants of virion stability and genome ejection," describes the structure of phage P7-1, which is included in Armata's multi-phage cocktail, AP-PA02.

Armata Pharmaceuticals Announces Appointment of Biopharmaceutical Commercial Executive Daniel B. Gilmer, Ph.D.

2026-04-27 07:00:00

LOS ANGELES, April 27, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that Daniel B. Gilmer, Ph.D.